CIK 0001590877
- Non-accelerated filer
- Smaller reporting company
REGENXBIO Inc.
Sign in to watch- Ticker
- RGNX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 471851754
- Phone
- +1 240-552-8181
- Business address
- 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
- Former names
- ReGenX Biosciences, LLC
- 4 Open-market sale Chief Financial Officer sold 5,000 shares at an average $37.56 ($187,797)
- 4 Open-market sale SVP, General Counsel sold 10,000 shares at $39.00 ($390,000)
- 4 Open-market sale SVP, General Counsel sold 10,000 shares at $34.00 ($340,000)
- 4 Open-market sale Chief Financial Officer sold 5,000 shares at $30.00 ($150,000)
- 4 Open-market sale President and CEO sold 10,000 shares at $29.55 ($295,500)
- 4 Open-market sale SVP, Technical Operations sold 25,000 shares at $33.00 ($825,000)
- 4 Exercise or conversion Chief Financial Officer acquired 60,000 shares (option exercise)
- 4 Open-market sale Chief Financial Officer sold 5,000 shares at $30.00 ($150,000)
- 4 Open-market sale President and CEO sold 10,000 shares at $26.56 ($265,600)
- 4 Open-market sale President and CEO sold 10,000 shares at $27.33 ($273,300)
- 4 Open-market sale Chief Financial Officer sold 5,000 shares at $30.16 ($150,800)
- 4 Exercise or conversion President and CEO acquired 150,000 shares (option exercise)
- 4 Exercise or conversion Chief Financial Officer acquired 30,000 shares (option exercise)
- 4 Grant or award SVP, General Counsel acquired 1,141 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale SVP, Technical Operations sold 30,000 shares at $33.03 ($990,900)
Page 16 of 22 · 435 filings